1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
PAVmed Inc.

PAVmed Inc.

PAVMW
PAVmed Inc.US flagNASDAQ Capital Market
0.03
USD
+0.01
- -
769,747.00Market Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
2
4
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
-10,878.6
-24,161.01
-2,805.67
-1,557.35
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
2
3
2
Net Income, GAAP
- -
-2
-6
-10
-18
-16
-34
-50
-89
-64
-58
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
-10,069.4
-23,602.92
-2,617.25
-1,508.12
Working Capital
1
- -
- -
-1
-3
-5
-1
75
3
-30
-23
LT Debt
- -
- -
- -
2
- -
- -
- -
- -
2
3
5
Total Equity
1
1
- -
-3
-2
-5
- -
79
11
-24
-19
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Dec'23
Mar'24
Jun'24
ST Debt
46
47
45
LT Borrowings
- -
- -
- -
LT Finance Leases
3
3
5
Preferred Equity and Hybrid Capital
3
3
3
Shares Outstanding
9
9
9
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Dec'23
Mar'24
Jun'24
Total Current Assets
24
30
30
Cash, Cash Equivalents & STI
20
26
25
Accounts Receivable, Net
- -
- -
- -
Inventories
1
1
1
Total Current Liabilities
54
55
53
Payables & Accruals
5
8
8
ST Debt
46
47
45
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-3,459.73%
-319.66%
Free Cash Flow
- -
50.39%
-27.92%
Net Income, GAAP
- -
39.12%
-27.88%
Sales/Revenue/Turnover
- -
- -
550.4%
Total Cash Common Dividend
- -
-10.55%
8.19%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
1
1
2
2024
1
1
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Lishan Aklog
Full Time Employees
25
Sector
Healthcare
Industry
Medical - Devices
Address
One Grand Central Place New York City NY United States of America 10165
IPO Date
Jul 28, 2016
CIK
0001624326
Website
pavmed.com
Similar Companies
Artivion, Inc. (AORT)
Össur hf. (OSSR.CO)
Theralase Technologies Inc. (TLTFF)
NIOX Group Plc (CSSPF)
Drägerwerk AG & Co. KGaA (DGWPF)
ClearPoint Neuro, Inc. (CLPT)
Business
PAVmed Inc. (Nasdaq: PAVM, PAVMW) operates as a diversified commercial-stage medical technology company focused on developing and commercializing innovative products across medical devices, diagnostics, and digital health sectors; its core offerings include Lucid Diagnostics' EsoGuard esophageal precancer detection test utilizing the EsoCheck cell collection device, Veris Health's remote patient monitoring platform and implantable physiological monitor for personalized cancer care, and pipeline technologies advanced through its PMX incubator such as PortIO implantable intraosseous vascular access device, EsoCure percutaneous esophageal stricture treatment system, and CarpX percutaneous carpal tunnel syndrome treatment device. Founded in 2014 and headquartered in New York City, the company serves physicians, patients, and healthcare systems primarily in the United States with plans for global expansion through subsidiaries targeting minimally invasive surgery, diagnostic imaging, and telehealth markets. Recent developments encompass Veris Health's strategic partnership and pilot program with The Ohio State University Comprehensive Cancer Center launched in 2024, a $2.5 million direct equity financing for Veris Health completed in June 2025 to support FDA submission of its monitor, Lucid Diagnostics' $29.8 million Series B preferred stock offering closed in May 2024 to bolster commercialization efforts including a new market access team and direct contracting initiatives, launch of the first EsoGuard mobile test unit and #CheckYourFoodTube precancer testing events for firefighters and at-risk groups in 2024-2025, establishment of the PMX incubator in March 2024 via joint venture with Hatch Medical to advance late-stage pipeline assets, and a letter of intent signed with Duke University in 2025 to license endoscopic imaging technology.

Company News

APIChat

  • thelincolnianonline.com

    PAVmed Inc (NASDAQ:PAVM) Sees Large Increase in Short Interest

  • finance.yahoo.com

    Edited Transcript of PAVM earnings conference call or presentation 9-Apr-20 8:30pm GMT

  • finance.yahoo.com

    The Daily Biotech Pulse: FDA Snub For Merck, Priority Review For Roche's Tecentriq sBLA

  • finance.yahoo.com

    The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data

  • finance.yahoo.com

    The Daily Biotech Pulse: PhaseBio To Buy Hypertension Asset, Stemline Falls On Q4 Pre-Announcement, FDA Panel To Review Nektar's Opioid Drug